文献速递儿科与产科急症

质子束治疗口咽癌(TORPEdO):一项3期随机对照试验

Proton beam therapy for oropharyngeal cancer (TORPEdO): a phase 3, randomised controlled trial.
PubMed 文献 · Lancet · 2026-03-21
一句话结论在局部晚期口咽鳞癌中,调强质子治疗与调强放疗的12个月晚期身体功能生活质量、胃造瘘管依赖、局部控制和总生存相似;在质子治疗非常规用于口咽鳞癌的医疗环境中,调强放疗仍是标准治疗。

TORPEdO是一项在20家英国国家医疗服务体系医院开展的3期随机对照试验,将205例局部晚期口咽鳞癌患者按2:1随机分配至调强质子治疗(IMPT)或调强放疗(IMRT),放疗剂量均为70 Gy/33次/6.5周,并联合两个周期大剂量顺铂(100 mg/m2,每3周一次)。12个月共同主要终点为胃造瘘管依赖或严重体重下降(较基线≥20%)以及华盛顿大学生活质量量表(UW-QoL)身体综合评分。结果显示,IMPT组与IMRT组在胃造瘘管依赖、严重体重下降、UW-QoL身体综合评分、局部区域复发和总生存方面均无显著差异。作者结论认为,在IMPT非常规用于口咽鳞癌的医疗环境中,IMRT仍是标准治疗。

要点

  • 在局部晚期口咽鳞癌中,IMPT与IMRT的12个月UW-QoL身体综合评分分别为78.3 vs 77.1,差值1.3(97.5%CI -3.7至6.2),无显著差异。
  • 12个月胃造瘘管依赖:IMPT组2%(2/119)vs IMRT组2%(1/59);严重体重下降:IMPT组18%(20/110)vs IMRT组6%(3/53),合并OR 2.80(97.5%CI 0.75至10.4),p=0.079,未达统计学显著。
  • 24个月局部区域复发自由率:IMPT组94%(99%CI 86-98)vs IMRT组97%(82-100),HR 2.6(99%CI 0.3至20.3;95%CI 0.5-12.4),p=0.24;总生存率两组均为95%,HR 1.6(99%CI 0.3至8.8;95%CI 0.4至5.9),p=0.47。
  • 12例患者发生14起严重不良事件,最常见为急性肾损伤(5例,36%)和血栓栓塞(4例,29%);无治疗相关死亡。
  • 作者结论:在IMPT非常规用于口咽鳞癌的医疗环境中,IMRT仍是标准治疗。

适用人群与场景

  • 局部晚期口咽鳞状细胞癌患者,来自20家英国国家医疗服务体系医院。
  • 纳入99例(48%)T3或T4期患者和44例(22%)双侧颈部淋巴结受累(N2[c])患者。
  • 205例中男性163例(80%),女性42例(20%);177例(86%)自报族裔,其中167例(94%)为英国白人。

处置流程与药物剂量

  • IMPT或IMRT放疗剂量均为70 Gy,分33次,疗程6.5周。
  • 联合两个周期大剂量顺铂,剂量100 mg/m2,每3周一次。

研究设计与关键结果

  • 3期随机对照试验(TORPEdO),在20家英国国家医疗服务体系医院开展,205例局部晚期口咽鳞癌患者按2:1随机分配至IMPT组(136例)或IMRT组(69例)。
  • 12个月胃造瘘管依赖:IMPT组2%(2/119)vs IMRT组2%(1/59)。
  • 12个月严重体重下降(较基线≥20%):IMPT组18%(20/110,97.5%CI 11至28)vs IMRT组6%(3/53,97.5%CI 1至17),合并OR 2.80(97.5%CI 0.75至10.4),p=0.079。
  • 12个月UW-QoL身体综合评分均值:IMPT组78.3 vs IMRT组77.1,差值1.3(97.5%CI -3.7至6.2),p=0.56。
  • 12例患者发生14起严重不良事件:9起评估为与研究治疗无关(IMPT组4起,IMRT组5起),5起为研究治疗相关(IMPT组1起 vs IMRT组4起);最常见为急性肾损伤(5例,36%)和血栓栓塞(4例,29%);无治疗相关死亡。
  • 中位随访28.3个月(IQR 26.5至39.3):24个月局部区域复发自由率IMPT组94%(99%CI 86-98)vs IMRT组97%(82-100),HR 2.6(99%CI 0.3至20.3;95%CI 0.5-12.4),p=0.24;总生存率IMPT组95%(86至98)vs IMRT组95%(81-99),HR 1.6(99%CI 0.3至8.8;95%CI 0.4至5.9),p=0.47。

证据类型、等级与局限

  • 证据类型:3期随机对照试验。
  • 资助:英国癌症研究基金会(Cancer Research UK)。
  • 注册号:ISRCTN16424014;招募已完成,随访正在进行中。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在IMPT非常规用于口咽鳞癌的医疗环境中,IMRT仍是标准治疗(作者结论)。
  • IMPT与IMRT在晚期身体生活质量评分、胃造瘘管依赖、局部控制和总生存方面相似(作者结论)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The clinical benefits of intensity-modulated proton therapy (IMPT) compared with intensity-modulated radiation therapy (IMRT) for patients with oropharyngeal squamous cell carcinoma remain uncertain with respect to treatment-related effects on physical function and quality of life. We aimed to compare late functional, patient-reported, disease control, and survival outcomes between IMPT and IMRT.

METHODS: We did a phase 3 trial (TORPEdO) in 20 UK National Health Service hospitals. We randomly assigned (2:1) patients with locally advanced oropharyngeal squamous cell carcinoma to IMPT or IMRT (70 Gy in 33 fractions, for 6·5 weeks) with two cycles of high-dose cisplatin (100 mg/m2, every 3 weeks). Co-primary endpoints at 12 months were gastrostomy-tube dependence (use of feeding tube for nutrition) or severe weight loss (≥20% from baseline) and University of Washington quality of life (UW-QoL) mean physical composite score for saliva, taste, chewing, swallowing, speech and appearance. The study was registered with the ISRCTN registry, ISRCTN16424014; recruitment is complete and follow-up is ongoing.

FINDINGS: Between Feb 25, 2020, and June 13, 2023, we randomly assigned 205 patients (99 [48%] with T3 or T4 disease and 44 [22%] with bilateral neck lymph node involvement (N2[c]); 136 [66%] to IMPT and 69 [34%] to IMRT). 163 (80%) patients were male and 42 (20%) were female. Ethnicity data were self-reported by 177 (86%) patients; most were White British (167 [94%]). At 12 months, gastrostomy-tube dependence occurred in two (2%) of 119 patients in the IMPT group and in one (2%) of 59 patients in the IMRT group and severe weight loss occurred in 20 (18% [97·5% CI 11 to 28]) of 110 patients in the IMPT group and in three (6% [1 to 17]) of 53 patients in the IMRT group (combined odds ratio 2·80 [97·5% CI 0·75 to 10·4]; p=0·079). Mean UW-QoL physical composite scores at 12 months were 78·3 in the IMPT group versus 77·1 in the IMRT group (difference 1·3 [97·5% CI -3·7 to 6·2]; p=0·56). There were 14 serious adverse events in 12 patients (nine assessed as unrelated to the study treatment [four in the IMPT group and five in the IMRT group] and five study treatment-related [one IMPT vs four IMRT]); the most common events were acute kidney injury (five [36%]) and thromboembolism (four [29%]). There were no treatment-related deaths. At a median follow-up of 28·3 months (IQR 26·5 to 39·3), 24-month freedom from loco-regional recurrence rates were 94% (99% CI 86-98) in the IMPT group versus 97% (82-100) in the IMRT group (hazard ratio [HR] 2·6 [99% CI 0·3 to 20·3; 95% CI 0·5-12·4]; p=0·24), and overall survival rates were 95% (86 to 98) in the IMPT group versus 95% (81-99) in the IMRT group (HR 1·6 [99% CI 0·3 to 8·8; 95% CI 0·4 to 5·9; p=0·47).

INTERPRETATION: IMPT and IMRT had similar late physical quality of life scores, gastrostomy-tube dependence, local control, and overall survival. In health-care settings where IMPT is not used routinely for oropharyngeal squamous cell carcinoma, IMRT remains the standard of care.

FUNDING: Cancer Research UK.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Thomson DJ, Price JM, Tyler M, et al. Proton beam therapy for oropharyngeal cancer (TORPEdO): a phase 3, randomised controlled trial. Lancet. 2026. PMID: 41875914. doi:10.1016/S0140-6736(26)00314-4

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。